A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure

A Clinical Study for Developing AI-based Clustering Model for Personalized Medicine in Acute Respiratory Failure: Single Center, Prospective Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06479421

Enrollment

250

Registered

2024-06-28

Start date

2023-08-14

Completion date

2029-04-30

Last updated

2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Failure

Keywords

phenotyping, clustering analysis

Brief summary

The investigators will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\# Inclusion Criteria: \- Acute Respiratory Failure group Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met: 1\) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure. \- control group For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure. 1. Age 18 or older 2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment *

Exclusion criteria

If any of the following criteria applies, participants will not be permitted to participate in this clinical trial. 1. Patients 48 hours after oxygen treatment (HFNC, NIV (BIPAP or CPAP), MV) 2. Patients transferred from another hospital 3. Patients with limitations in treatment

Design outcomes

Primary

Measure	Time frame	Description
Hospital Mortality	From date of admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 1 year	clinical outcomes - Hospital Mortality

Secondary

Measure	Time frame	Description
ICU Mortality	From date of ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 6 months	clinical outcomes - ICU Mortality
Hospital length of stay	From date of hospital admission until the date of hospital discharge, assessed up to 1 years	clinical outcomes - Hospital length of stay
ICU length of stay	From date of ICU admission until the date of ICU discharge, assessed up to 6 months	clinical outcomes - ICU length of stay

Countries

South Korea

Contacts

CONTACTRyoung Eun Ko, MD, PhD

koryoungeun@gmail.com+82-2-3410-6399

Outcome results